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tures account for only between 3% and 6% of total health care
spending per capita. Yet the contribution of medical devices is
essential to delivering improved clinical and economic beneﬁts for
patients and health care systems, respectively. We brieﬂy report a
selective overview of reimbursement coverage and pricing systems
for single-use devices (SUDs) in Japan, Taiwan, Korea, and Aus-
tralia, major Asia-Paciﬁc markets with diverse health care systems
but similar challenges. Generally speaking, all four health systems
are similar in their framework for managing the coverage and
reimbursement of SUDs, which are usually bundled into the overall
fee designated for a surgical procedure; however, funding guide-
lines are unclear and decision-making processes opaque. Unfortu-ee front matter Copyright & 2015, International S
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ndence to: Sang-Soo Lee, Medtronic Korea Ltd., 4F,nately, this inequitable situation encourages both the dangerous
practice of reuse of devices and the imposition of additional out-of-
pocket costs on patients. Reimbursement pathways in all four
countries need to evolve to accommodate new methods of deliver-
ing health care, with fair decision-making processes for reimburse-
ment coverage and pricing, which assess the overall value of
medical devices, including SUDs, in terms of health outcomes
and/or safety.
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In general, including in Asia-Paciﬁc countries, medical device
expenditures account for only a small proportion (between 3%
and 6%) of total health care spending per capita [1]. Yet the
contribution of medical devices is essential to delivering
improved clinical and economic beneﬁts for patients and health
care systems, respectively.
The US Food and Drug Administration broadly deﬁnes a
medical device as “an instrument, apparatus, implement, machine,
contrivance, implant, in vitro reagent, or other similar or related
article, which is used to diagnose, prevent, or treat disease or
other conditions, and does not achieve its purposes through
chemical action within or on the body” [2]. Similarly broad
deﬁnitions apply in other countries, and as a result medical
devices vary greatly in complexity and application, and different
health care systems have similar issues managing their
regulation and reimbursement. Various kinds of technologies
exist, including prosthetic implants, which replace or modifyanatomical functioning and are required over the long term, e.g.,
coronary stents, pacemakers, and artiﬁcial knees, and single-use
devices (SUDs), which are nonimplantable and not designed for
reuse and vary in sophistication from having a speciﬁc thera-
peutic or diagnostic use (e.g., atrial ﬁbrillation ablation catheters
and drug-coated balloons) to devices acting as adjuncts to the
delivery of therapeutic interventions (e.g., catheters, guidewires,
and sheaths) to “consumable items” (e.g., disposable plastic
syringes and latex surgical gloves). As the uses and roles of SUDs
increase, their effects on reimbursement coverage and pricing
processes and policies are in growing need of attention from
health authorities and other payers.
Four Asia-Paciﬁc countries, Japan, Taiwan, Korea, and Aus-
tralia, have diverse health care systems with unique challenges
for patient access to medical services but also share similarities
(Table 1). Here, we brieﬂy report a selective overview of reim-
bursement coverage and pricing systems for SUDs in these major
Asia-Paciﬁc markets, where comprehensive public or private
health care systems exist.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Table 1 – Health care systems in four Asia-Paciﬁc countries: Selective comparisons.
Key aspects
Health care system
Japan Taiwan Korea Australia
Health insurance
system
National health
insurance
(multiple payer)
National health
insurance (single
payer)
National health insurance
(single payer)
Public health insurance,
private health
insurance
Decision maker for
reimbursement
coverage and pricing
Ministry of Health,
Labor and
Welfare (MHLW)
Ministry of Health and
Welfare (MoHW)
MoHW, Health Insurance
Review and Assessment
Service (HIRA)
Department of Health
Total health care
expenditure as
percentage of GDP*
10.1 6.9 (2011) 7.5 9.1
Payment system for
medical devices
Fee-for-service
(FFS)
FFS, Diagnostic Related
Group (DRG), Global
budget system
FFS, DRG† Prostheses List (private
insurance), DRG
(public insurance)
Medical device
reimbursement
management system
Functional
category system
Functional category
system
Functional category system Functional category
system
GDP, gross domestic product.
* 2012 data [3].
† DRG is limited to seven disease groups in Korea.
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Japan has a national health insurance system, and medical
devices are mostly paid for under a “fee-for-service” scheme.
Reimbursement decision-making processes and prices differ by
product group. Medical devices available in Japan are classiﬁed by
generic name, which provides a broad deﬁnition of the device
with further subdivision based on risk category. Most low-risk
medical devices (i.e., US Food and Drug Administration class I
and II devices) do not have separate reimbursement prices and
their payment is included in the procedure fee (which also
includes patient management fees); likewise, low-risk SUDs are
bundled into the procedure fee. Manufacturers must submit a
reimbursement application to the Ministry of Health, Labor and
Welfare (MHLW) for their SUD device to be covered by particular
procedure fees. Medium- and high-risk SUDs, in general, have
their individual reimbursement prices determined by the MHLW
on the basis of the “functional category” system. Functional
category is determined by the MHLW, but reﬂects the opinion
of the Central Social Medical Insurance Council (“Chuikyo”),
which also determines which medical devices are to be included
under national insurance. The criteria for deﬁning the functional
category of a device are based on similarity in structure, purpose
of use, efﬁcacy, and effectiveness/performance. Manufacturers
need to submit an application to the MHLW to get their devices
into an existing functional category (if an applicable one exists) to
be covered by reimbursement. If a new medical device does not
ﬁt into an existing functional category and/or corresponding
procedure fee, manufacturers need to submit an application to
the MHLW to create a new functional category or to develop both
a new functional category and a new procedure fee to acquire
reimbursement for their device.Taiwan
Taiwan has a national health insurance system, and medical
devices are paid for either under a fee-for-service or a Diagnosis
Related Group (DRG)-based scheme. Medical devices are reim-
bursed on the basis of a functional category classiﬁcation, with
the categories deﬁned by the National Health InsuranceAdministration using criteria based on similarity in structure,
purpose of use, efﬁcacy, and performance [4]. The Pharmaceutical
Beneﬁts and Reimbursement Schedule committee, composed of
various stakeholders, reviews reimbursement coverage, the pro-
posed price, and any restrictions; however, the National Health
Insurance Administration makes the ﬁnal decision on reimburse-
ment coverage and price. With the amended and promulgated
“Second Generation” National Health Insurance Act in 2011, a
“Balance Billing” system was introduced so that patients would
take greater ﬁnancial responsibility for expenditure on more
costly medical devices. The National Health Insurance Admin-
istration makes the decision on the reimbursement price of new
devices by comparing the prices of currently listed devices and
referring to the reimbursement or market prices in other coun-
tries [5].
Reimbursement coverage decisions for medical devices are
classiﬁed into three categories: “reimbursed,” “funding under pro-
cedure fee,” and “unreimbursed (funded by patients out-of-pocket).”
Many SUDs are placed in the funding under procedure fee
category. Unfortunately, Pharmaceutical Beneﬁts and Reimburse-
ment Schedule decisions about SUDs are often made without
clarity of procedure or process, and are therefore unpredictable,
making it difﬁcult for manufacturers to plan their reimbursement
application strategy. The overall result of funding SUDs under
procedure fees creates a market entry barrier, and, worse,
encourages the unsafe practice of reusing SUDs.Korea
Korea has a national health insurance system, and medical
devices are paid for under a fee-for-service or a DRG-based
scheme (though the latter is limited to only seven disease
groups). Medical devices are reimbursed on the basis of func-
tional category, with the categories deﬁned by the Ministry of
Health and Welfare (MoHW) after considering indication for use
and three physical characteristics: compositional material, shape,
and size [6]. The formal decisions about reimbursement coverage
and price are made by the MoHW, but in practice the decisions
are made by the Medical Device Expert Evaluation Committee
within the Health Insurance Review and Assessment Services.
Medical Device Expert Evaluation Committee’s reimbursement
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of currently listed devices. Similar to Taiwan and Japan, medical
devices are classiﬁed into one of three categories: reimbursed,
funding under procedure fee, and unreimbursed. The ﬁrst two
categories are collectively regarded as “reimbursement” catego-
ries, and many SUDs are paid for under one or the other.
Unfortunately, for the funding under procedure fee category,
there are no clear deﬁnitions or guidelines for SUDs; thus,
decision making lacks transparency and consistency. In addition,
there appears to be bureaucratic reluctance to properly examine
the evidence supporting the value of new SUDs, or to address the
issue of outdated procedural costings. As a result, often new
SUDs, which are in fact dissimilar to listed products, are simply
placed into established groupings irrationally. Because, in many
cases, the costs of new SUDs are signiﬁcantly higher than the
corresponding procedure fee, this situation not only hinders
market access but also encourages health care providers to reuse
SUDs. Ironically, although the Ministry of Food and Drug Safety
(formerly the Korea Food and Drug Administration) strictly
prohibits the reuse of SUDs, the MoHW sets procedure fees by
incorporating an anticipated SUD reuse rate; for instance, the
procedure fee for Intraoperative Neurophysiologic Monitoring
incorporates a reuse rate for two SUDs, electrode-subdermal
needle and electrode-electroencephalogram, of 4 times and 50
times, respectively [7]. Although the MoHW has a process for
reviewing procedure fees (with detailed cost analysis) every 5
years, the revisions have not been undertaken rigorously, adding
to the disappointment of suppliers, providers, and patients and
facilitating the problem of SUD reuse.Australia
Australia has both a national tax-based health system and a
voluntary private health insurance system. In the national health
system, medical devices are funded within a DRG-based prospec-
tive case payment, which includes hospital and physician costs.
Medical devices are predominantly supplied under tendering
arrangements, and the range and choice of device can be limited.
However, in the private health insurance–based system, medical
devices are mainly funded via the Prostheses List (PL), a register
of devices administered by the Department of Health. Private
health insurers are required to pay a “beneﬁt” (reimbursement)
for a prosthesis that is provided as part of an episode of inpatient
hospital treatment but only if the device is included on the PL.
The relevant legislation does not deﬁne a “prosthesis”; instead,
criteria for listing products on the PL are applied to each medical
device assessed on application for listing.
The PL is based on a functional category system and lists both
the medical devices and the corresponding beneﬁt amounts that
private health insurers are required to reimburse (in addition to
the predominantly DRG-based payment for hospital charges).
Within the various functional categories listed on the PL, medical
devices are grouped according to the features and characteristics
that deﬁne their clinical effectiveness. Medical devices consid-
ered to have similar clinical effectiveness are listed with similar
beneﬁts (reimbursement prices).
Unfortunately, SUDs with a speciﬁc therapeutic or diagnostic
use (also known as “high-cost disposable products”) are not
eligible for inclusion on the PL because they are not surgically
implanted or remain with the patient after discharge from
hospital. Under the DRG model, funding for these devices is
bundled into the overall case payment. Unlike most surgical
theater consumables, which are routinely used and relatively
cheap, however, sophisticated SUDs tend to be of higher cost, and
without mandated additional payments to cover their costs,
access to SUDs is determined by individual contractualarrangements between the private health insurer and the private
hospital. As a result, patient access to SUDs varies across the
country, for example, access to catheter ablation devices for the
treatment of atrial ﬁbrillation. The difference in funding arrange-
ments for implanted versus nonimplanted devices also risks
creating a perverse incentive to use potentially less effective
and in the long run perhaps more costly treatment options, for
example, stents (separately reimbursed) instead of drug-coated
balloon technologies (DRG-funded) to treat peripheral and coro-
nary arterial disease [8].Discussion
The four Asia-Paciﬁc countries reviewed here display both sim-
ilarities and differences in the elements of reimbursement cover-
age and pricing decision making for implantable devices and
SUDs. Japan, Taiwan, and Korea in particular have very similar
frameworks in terms of the overall management of SUD coverage
and reimbursement. Although many SUDs are grouped in a
category that provides for separate funding, a considerable
number are bundled into the procedure fee; this raises a number
of problems, as outlined above.
There are other important issues around how SUDs are
funded and access to them. First, the countries reviewed do not
have clear guidelines and processes for managing the reimburse-
ment of SUDs. There are no clear criteria for determining which
reimbursement category SUDs will be funded under. This often
results in poor transparency of decision making, and uncertainty
for manufacturers and other stakeholders.
Second, although health authorities systematically evaluate
the clinical and economic value of most implantable devices, they
usually do not assess SUDs in the same way but simply bundle
them into procedure fees. As a result, the beneﬁts of innovative
SUDs, as well as their costs, are not properly considered.
Third, inequitable funding arrangements for SUDs raises the
risk of two different but serious issues that may have an impact
on patients: the problem of reuse of devices not designed to be
safely recycled, and the imposition of out-of-pocket payments on
patients, both a result of health care providers attempting to keep
costs within procedure fee thresholds.Conclusions
The four Asia-Paciﬁc countries reviewed here do not have
equitable arrangements for managing the reimbursement of
sophisticated SUDs, and the processes currently in place run
the risk of encouraging the unfair practice of demanding out-of-
pocket payments from patients, and, worse, the dangerously
unsafe practice of recycling devices. What are required are clear
guidelines for reimbursement coverage and pricing, and trans-
parent and fair evaluation and decision-making processes, so
that the value of an SUD, in terms of health outcomes and/or
safety, is properly taken into account. This requires reimburse-
ment pathways in all four countries to evolve to accommodate
new treatment options and methods of delivering health care,
which may be less invasive and resource intensive due to
innovative SUDs (e.g., ablation catheters now provide an alter-
native treatment option to open surgery for Barrett’s esophagus).
One way forward may be to develop processes that do not
separate implantable from nonimplantable devices but focus
more on assessing holistically the value device products bring
to patients and health care providers and payers, and linking this
to reimbursement support, so that the use of a particular device
is based on the most appropriate treatment option rather than
the somewhat arbitrary availability of funding.
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responsibility for developing the clinical and economic evidence
necessary for health care providers and payers in the four
markets reviewed here to understand the value of a new
technology, and particularly how it compares to alternative
treatment options. Reimbursement and pricing decisions can
then be transparently and rationally made on the basis of
evidence rather than artiﬁcial barriers based on inﬂexible and
out-of-date criteria.
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